Last reviewed · How we verify
A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS)
Compare Clinical Success and Costs in two Arms
Details
| Lead sponsor | Canyon Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 4 |
| Status | TERMINATED |
| Enrolment | 16 |
| Start date | 2008-09 |
| Completion | 2009-12 |
Conditions
- Suspected Heparin-Induced Thrombocytopenia
Interventions
- Desirudin or Argatroban®
Primary outcomes
- New Thrombosis, Amputation, Death, Major and Minor Bleeding — 30 days
Countries
United States